TABLE 1.
Characteristics of study participants
| Characteristic | SP every 8 wks (N = 106) | DHA-PQ every 8 wks (N = 94) | DHA-PQ every 4 wks (N = 100) |
|---|---|---|---|
| Age (years) (mean [SD]) | 21 (3.6) | 22 (4.3) | 23 (4.0) |
| Gravidity (n [%]) | |||
| 1 | 42 (40) | 33 (35) | 36 (36) |
| 2 | 32 (30) | 28 (30) | 28 (28) |
| ≥3 | 32 (30) | 33 (35) | 36 (36) |
| Gestational age (wks) at first study drug treatment (%) | |||
| 16 | 68 | ||
| 20 | 106 | 94 | 32 |
| No. of PQ concn observations | |||
| Venous | 300 | 352 | |
| Capillary | 278 | 280 | |
| Visits after participant received indoor residual spraying of insecticide (n) | 101 | 101 | 153 |
| First episodes of parasitemia after each administration of study drug (n)a | 140 | 37 | 30 |
| Genotypes (n [%]) | |||
| pfmdr1 N86Y genotype available | 117 (84) | 37 (100) | 28 (93) |
| pfmdr1 86Y | 32 (27) | 18 (49) | 24 (86) |
| pfcrt K76T genotype available | 122 (87) | 37 (100) | 28 (93) |
| pfcrt 76T | 92 (82) | 31 (84) | 26 (93) |
a
Artemeter-lumefantrine (AL) was used to treat malaria during the study. To avoid consideration of the effects of AL on repeated observations of the same parasites, parasitemia detected after treatment with AL and before subsequent receipt of DHA-PQ or parasites detected repeatedly without interval receipt of DHA-PQ were excluded.